Amylyx Pharmaceuticals (AMLX) Current Assets (2021 - 2026)

Amylyx Pharmaceuticals has reported Current Assets for 6 years, with the latest figure at $256.3 million in Q2 2026.

• On a quarterly basis, Current Assets rose 37.16% year-over-year to $256.3 million in Q2 2026; TTM through Jun 2026 was $256.3 million, a 37.16% increase from a year earlier, with the FY2025 full-year figure at $323.7 million, up 70.86% from the prior year.
• Current Assets was $256.3 million for Q2 2026 at Amylyx Pharmaceuticals, down from $285.0 million in the prior quarter.
• The five-year high for Current Assets was $464.7 million in Q4 2023, with the low at $172.2 million in Q3 2022.
• Average Current Assets over 5 years is $308.0 million, with a median of $304.3 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2024: Current Assets surged 264.11% in 2022, then sank 59.23% in 2024.
• Over 5 years, Current Assets stood at $382.1 million in 2022, then increased by 21.6% to $464.7 million in 2023, then tumbled by 59.23% to $189.4 million in 2024, then soared by 70.86% to $323.7 million in 2025, then slipped by 20.8% to $256.3 million in 2026.
• The last three Current Assets figures came in at $256.3 million (Q2 2026), $285.0 million (Q1 2026), and $323.7 million (Q4 2025), per Business Quant data.